Clinical trials
Relapsed clinical trials
Below are recruiting relapsed clinical trials, each written for real people, not researchers. We’re tracking 907 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06219356RecruitingPhase 1
Study of GLB-002 for relapsed or refractory non-Hodgkin lymphoma
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06222580RecruitingPhase 1
Combination of two targeted drugs for resistant FLT3-mutated AML
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
Chapel Hill, North CarolinaAges 18 years+ - NCT06223880RecruitingPhase 4
AXS-05 vs Bupropion to prevent depression relapse
This study tests whether a new drug called AXS-05 can prevent depression from coming back, compared to an older drug called bupropion. If you have major depression and are at risk of relapse, this trial may help you stay well.
Bellflower, CaliforniaAges 18–65 - NCT06224049RecruitingEarly Phase 1
New immune cells for Epstein-Barr virus positive T-cell lymphoma
This trial tests a new treatment using specially designed immune cells (called hNeo-T cells) to attack Epstein-Barr virus positive T-cell lymphoma that has come back or not responded to standard therapy. The treatment is personalized based on your tumor's unique markers and your tissue type (HLA).
Shenzhen, GuangdongAges 18–75 - NCT06225310RecruitingPhase 1
New combo for relapsed/refractory multiple myeloma
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
West Hollywood, CaliforniaAges Any age - NCT06232096RecruitingPhase 1/Phase 2
Study of MBS314 for relapsed or refractory multiple myeloma
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
BeijingAges 18 years+ - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06244641Recruiting
New Model for Relapse in Alcohol Use Disorder
This study is testing a new way to understand and predict relapse in people with alcohol use disorder. If you're currently hospitalized for this condition, researchers want to learn from your experience to improve care.
Brussels, Brussels CapitalAges 18 years+ - NCT06251076RecruitingPhase 4
Outpatient teclistamab for multiple myeloma: a safety study
This study tests whether giving the drug teclistamab (a treatment for multiple myeloma) in an outpatient setting is safe and works well. You may qualify if you have had at least three prior treatments, have a caregiver to support you, and meet other health criteria.
Toronto, OntarioAges 18 years+ - NCT06252298RecruitingPhase 1
Testing a new drug for CD38-positive blood cancers
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06252675RecruitingPhase 2
Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Davis, CaliforniaAges 18 years+ - NCT06262386Recruiting
Predicting lung cancer return after surgery
This study tests a new way to predict if non-small cell lung cancer will return after surgery. You will give blood samples to look for cancer cells, and the team will build a model to help plan better follow-up care.
Taoyuan CityAges 20–90 - NCT06276634Recruiting
Low-Oxygen Therapy for People With Multiple Sclerosis
This study tests whether brief, controlled low-oxygen episodes (called intermittent hypoxia) can improve motor function in people with MS. It may help strengthen walking and daily movement.
Chicago, IllinoisAges 18–75 - NCT06296121RecruitingPhase 3
BCD-264 vs Darzalex for relapsed multiple myeloma
This trial tests a new drug, BCD-264, compared to Darzalex (daratumumab) alone for people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see if BCD-264 works better than Darzalex in controlling the cancer.
ChelyabinskAges 18 years+ - NCT06297226RecruitingPhase 2
CAR T cell therapy for multiple myeloma
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
Birmingham, AlabamaAges 18 years+ - NCT06299553Recruiting
Study of tafasitamab with lenalidomide for relapsed DLBCL patients
This study looks at how well a combination of two drugs, tafasitamab and lenalidomide, works for people with a type of lymphoma (DLBCL) that has come back or hasn't responded to treatment. After the combination, patients continue with tafasitamab alone. This is for patients who cannot have a stem cell transplant.
MilanAges 18 years+ - NCT06307054RecruitingPhase 1
CLL-1 CAR-NK cells for relapsed or refractory AML
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06311227RecruitingPhase 2
Venetoclax for relapsed hairy cell leukemia
This trial tests a targeted pill called venetoclax for people whose hairy cell leukemia has returned after other treatments. It aims to see if venetoclax can help control the disease and improve blood counts.
Duarte, CaliforniaAges 18 years+ - NCT06313957RecruitingPhase 1
Study of LUCAR-20SP for relapsed B-cell lymphoma
This trial tests a new treatment called LUCAR-20SP for people with certain types of B-cell lymphoma that have come back or not responded to prior therapy. The drug is a type of CAR-T therapy that targets the CD20 protein on lymphoma cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06316960RecruitingPhase 2
Avapritinib for children with relapsed or resistant CBF-AML and KIT mutation
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
Hefei, AnhuiAges Up to 18 years - NCT06326008RecruitingPhase 1
Donor immune cell therapy for leukemia that returned after treatment
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
Beijing, Beijing MunicipalityAges 1–18 - NCT07695012RecruitingEarly Phase 1
CAR-T cell therapy for B-cell acute lymphoblastic leukemia
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
RawalpindiAges 5–50 - NCT05672251RecruitingPhase 2
Testing two antibody drugs for lymphoma that came back
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Duarte, CaliforniaAges 18 years+ - NCT06746155Recruiting
Predictors of relapse in major depression
This study looks at adults with major depressive disorder who have responded to treatment, to find out what might predict a relapse. You will wear a wrist activity monitor and complete questionnaires.
Calgary, AlbertaAges 18–70
Hear when a new Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed?
- Yes. Clin2 currently lists 907 recruiting relapsed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.